T2 Biosystems Inc provides rapid in vitro diagnostic tests. Its panels are focused on bacterial sepsis infections, hemostasis, and Lyme disease. Its core technology is the T2 magnetic resonance platform, which can detect a variety of targets, including DNA, proteins, and hemostasis measurements. Using this technology, the firm has also developed the T2Dx, a benchtop instrument that can be used to detect sepsis and Lyme disease, among other applications. The T2Dx is fully automated from patient sample to result and includes panels for Candida and other bacteria that can lead to sepsis.